vs
Arhaus, Inc.（ARHS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Arhaus, Inc.的季度营收约是Orthofix Medical Inc.的1.7倍（$364.8M vs $219.9M），Arhaus, Inc.净利率更高（4.1% vs -1.0%，领先5.1%），Arhaus, Inc.同比增速更快（5.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-8.8M），过去两年Arhaus, Inc.的营收复合增速更高（11.2% vs 8.0%）
Arhaus, Inc.是源自美国的高端家居零售企业，总部位于俄亥俄州波士顿高地，1986年正式创立。品牌主打可持续理念与工匠级品质，产品品类丰富，采用全渠道模式面向个人消费者及企业客户，覆盖民用与商用家居场景，提供相关产品与配套服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ARHS vs OFIX — 直观对比
营收规模更大
ARHS
是对方的1.7倍
$219.9M
营收增速更快
ARHS
高出3.2%
2.0%
净利率更高
ARHS
高出5.1%
-1.0%
自由现金流更多
OFIX
多$25.6M
$-8.8M
两年增速更快
ARHS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $364.8M | $219.9M |
| 净利润 | $15.1M | $-2.2M |
| 毛利率 | 38.1% | 71.1% |
| 营业利润率 | 5.6% | 0.2% |
| 净利率 | 4.1% | -1.0% |
| 营收同比 | 5.1% | 2.0% |
| 净利润同比 | -29.1% | 92.4% |
| 每股收益（稀释后） | $0.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARHSOFIX
| Q4 25 | $364.8M | $219.9M | ||
| Q3 25 | $344.6M | $205.6M | ||
| Q2 25 | $358.4M | $203.1M | ||
| Q1 25 | $311.4M | $193.6M | ||
| Q4 24 | $347.0M | $215.7M | ||
| Q3 24 | $319.1M | $196.6M | ||
| Q2 24 | $309.8M | $198.6M | ||
| Q1 24 | $295.2M | $188.6M |
净利润ARHSOFIX
| Q4 25 | $15.1M | $-2.2M | ||
| Q3 25 | $12.2M | $-22.8M | ||
| Q2 25 | $35.1M | $-14.1M | ||
| Q1 25 | $4.9M | $-53.1M | ||
| Q4 24 | $21.3M | $-29.1M | ||
| Q3 24 | $9.9M | $-27.4M | ||
| Q2 24 | $22.2M | $-33.4M | ||
| Q1 24 | $15.1M | $-36.0M |
毛利率ARHSOFIX
| Q4 25 | 38.1% | 71.1% | ||
| Q3 25 | 38.7% | 72.2% | ||
| Q2 25 | 41.4% | 68.7% | ||
| Q1 25 | 37.1% | 62.8% | ||
| Q4 24 | 40.0% | 69.0% | ||
| Q3 24 | 38.6% | 68.7% | ||
| Q2 24 | 40.1% | 67.8% | ||
| Q1 24 | 39.0% | 67.5% |
营业利润率ARHSOFIX
| Q4 25 | 5.6% | 0.2% | ||
| Q3 25 | 4.8% | -8.3% | ||
| Q2 25 | 13.0% | -7.9% | ||
| Q1 25 | 1.7% | -25.2% | ||
| Q4 24 | 8.2% | -5.3% | ||
| Q3 24 | 3.3% | -9.6% | ||
| Q2 24 | 9.5% | -12.5% | ||
| Q1 24 | 6.2% | -15.6% |
净利率ARHSOFIX
| Q4 25 | 4.1% | -1.0% | ||
| Q3 25 | 3.5% | -11.1% | ||
| Q2 25 | 9.8% | -6.9% | ||
| Q1 25 | 1.6% | -27.4% | ||
| Q4 24 | 6.1% | -13.5% | ||
| Q3 24 | 3.1% | -13.9% | ||
| Q2 24 | 7.2% | -16.8% | ||
| Q1 24 | 5.1% | -19.1% |
每股收益（稀释后）ARHSOFIX
| Q4 25 | $0.11 | $-0.05 | ||
| Q3 25 | $0.09 | $-0.57 | ||
| Q2 25 | $0.25 | $-0.36 | ||
| Q1 25 | $0.03 | $-1.35 | ||
| Q4 24 | $0.15 | $-0.76 | ||
| Q3 24 | $0.07 | $-0.71 | ||
| Q2 24 | $0.16 | $-0.88 | ||
| Q1 24 | $0.11 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $253.4M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $418.2M | $450.0M |
| 总资产 | $1.4B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARHSOFIX
| Q4 25 | $253.4M | $82.0M | ||
| Q3 25 | $262.2M | $62.9M | ||
| Q2 25 | $234.8M | $65.6M | ||
| Q1 25 | $214.4M | $58.0M | ||
| Q4 24 | $197.5M | $83.2M | ||
| Q3 24 | $177.7M | $30.1M | ||
| Q2 24 | $174.2M | $26.4M | ||
| Q1 24 | $233.2M | $27.0M |
总债务ARHSOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益ARHSOFIX
| Q4 25 | $418.2M | $450.0M | ||
| Q3 25 | $400.4M | $442.5M | ||
| Q2 25 | $385.6M | $458.3M | ||
| Q1 25 | $348.8M | $458.3M | ||
| Q4 24 | $343.7M | $503.1M | ||
| Q3 24 | $320.6M | $525.9M | ||
| Q2 24 | $309.3M | $546.0M | ||
| Q1 24 | $285.6M | $570.3M |
总资产ARHSOFIX
| Q4 25 | $1.4B | $850.6M | ||
| Q3 25 | $1.4B | $832.6M | ||
| Q2 25 | $1.3B | $837.2M | ||
| Q1 25 | $1.3B | $823.1M | ||
| Q4 24 | $1.2B | $893.3M | ||
| Q3 24 | $1.2B | $867.9M | ||
| Q2 24 | $1.2B | $882.0M | ||
| Q1 24 | $1.2B | $906.0M |
负债/权益比ARHSOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-8.8M | $16.8M |
| 自由现金流率自由现金流/营收 | -2.4% | 7.6% |
| 资本支出强度资本支出/营收 | 5.0% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.62× | — |
| 过去12个月自由现金流最近4个季度 | $59.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ARHSOFIX
| Q4 25 | $9.3M | $27.7M | ||
| Q3 25 | $46.1M | $12.4M | ||
| Q2 25 | $34.9M | $11.6M | ||
| Q1 25 | $46.5M | $-18.4M | ||
| Q4 24 | $31.7M | $23.7M | ||
| Q3 24 | $31.1M | $11.7M | ||
| Q2 24 | $47.5M | $9.0M | ||
| Q1 24 | $36.8M | $-18.6M |
自由现金流ARHSOFIX
| Q4 25 | $-8.8M | $16.8M | ||
| Q3 25 | $28.0M | $2.5M | ||
| Q2 25 | $20.9M | $4.5M | ||
| Q1 25 | $18.9M | $-25.1M | ||
| Q4 24 | $13.0M | $15.2M | ||
| Q3 24 | $4.6M | $6.3M | ||
| Q2 24 | $11.3M | $-360.0K | ||
| Q1 24 | $10.9M | $-29.1M |
自由现金流率ARHSOFIX
| Q4 25 | -2.4% | 7.6% | ||
| Q3 25 | 8.1% | 1.2% | ||
| Q2 25 | 5.8% | 2.2% | ||
| Q1 25 | 6.1% | -13.0% | ||
| Q4 24 | 3.7% | 7.0% | ||
| Q3 24 | 1.4% | 3.2% | ||
| Q2 24 | 3.6% | -0.2% | ||
| Q1 24 | 3.7% | -15.4% |
资本支出强度ARHSOFIX
| Q4 25 | 5.0% | 4.9% | ||
| Q3 25 | 5.3% | 4.8% | ||
| Q2 25 | 3.9% | 3.5% | ||
| Q1 25 | 8.9% | 3.5% | ||
| Q4 24 | 5.4% | 4.0% | ||
| Q3 24 | 8.3% | 2.7% | ||
| Q2 24 | 11.7% | 4.7% | ||
| Q1 24 | 8.8% | 5.6% |
现金转化率ARHSOFIX
| Q4 25 | 0.62× | — | ||
| Q3 25 | 3.77× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 9.53× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 3.14× | — | ||
| Q2 24 | 2.14× | — | ||
| Q1 24 | 2.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARHS
| Sales Channel Retail | $305.7M | 84% |
| Sales Channel E Commerce | $59.2M | 16% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
